Breaking News

BioSig Technologies announced that the Company entered into a technical collaboration with Reified Capital, a provider of advanced artificial intelligence-focused technical advisory services to the private sector. Reified was co-founded by Dr. Alexander D. Wissner-Gross and Timothy M. Sullivan, the founders of Gemedy. The new collaboration with Cambridge, Massachusetts-based Reified will focus on developing a foundational artificial intelligence platform on the basis of integrated healthcare datasets, beginning with ECG and EEG data acquired by BioSig's first product, PURE EP System - a novel real-time signal processing platform engineered to provide electrophysiologists with high fidelity cardiac signals. Electrophysiology focused technological solutions developed under the terms of this collaboration will be integrated into the PURE EP technology platform. Reified is led by Harvard- and MIT-trained computer scientist and physicist Dr. Wissner-Gross, an award-winning computer scientist, physicist, entrepreneur and author. Technical expertise that the Reified team is planning to bring to the project includes data analysis, algorithmic modeling and development.

BioSig Technologies announced that the Company and its majority-owned subsidiary signed three new patent and know-how license agreements with Mayo Foundation for Medical Education and Research. Under the terms of the newly reached agreements the Company plans to establish a new product pipeline to complement more advanced features of BioSig's first product, PURE EP System, and develop solutions for novel ways to treat autonomic nervous system disease. The new R&D pipeline includes hardware, software and algorithmic solutions to be integrated into PURE EP platform technology. BioSig intends to take the licensed intellectual properties and products, which have been developed by Mayo Clinic over the last decade, through FDA approval, manufacturing, and commercialization. The development program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic's Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. The Company signed a 10-year collaboration agreement with Mayo Clinic in March 2017. On November 21, 2019 the Company announced that it commenced patient enrollment in its first clinical trial for the PURE EP System. Mayo Clinic and Dr. Asirvatham have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

BioSig Technologies announced that the Company commenced its first clinical trial for its PURE EP System. Texas Cardiac Arrhythmia Research Foundation in Austin, Texas, is the first institution to conduct patient cases under the clinical trial titled, "Novel Cardiac Signal Processing System for Electrophysiology Procedures". Eight patient enrollments were achieved during the first week of the trial. The data collected during the trial is planned to be submitted for abstract consideration at leading industry events throughout 2020, including The Heart Rhythm Scientific Sessions in May 2020.

BioSig Technologies announced that the Company supported the launch of the Alliance for Advancing Bioelectronic Medicine, an independent network of professionals united to support bioelectronic medicine. The alliance grew out of an invitation-only roundtable and working group that BioSig organized earlier this year, at which a group of researchers, entrepreneurs, and healthcare experts agreed on the need for a collaborative effort to create a shared vision for bioelectronic medicine. The Alliance for Advancing Bioelectronic Medicine aims to play a unique convening role, mobilizing patients, physicians, and other stakeholders to advocate for the field, and increasing awareness among audiences that are important for the field's growth, including policymakers, investors, media, and the general public. Its steering committee includes experts with experience at the Mayo Clinic, the Heart Rhythm Society, the European Heart Rhythm Association, The Feinstein Institute, RAND Corporation, Battelle, Imperial College London, and Sheba Medical Center.